Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Part 3 of an ongoing 12-part COVID-19 series, Sharon Lewin, AO, FRACP, PhD, FAAHMS, provides a brief update on the latest incidence trends and a concise guide to the management of mild and moderate disease. After the update, Dr. Lewin answers critical clinician questions on COVID-19 transmission, diagnosis, and management.
Content based on an online CME program supported by an independent educational grant from Gilead Sciences.
Link to full program: https://www.clinicaloptions.com/infectious-disease/programs/covid19-resources
Director, The Peter Doherty Institute for Infection and Immunity
Professor of Infectious Diseases
Faculty Medicine Dentistry and Health Sciences
University of Melbourne and Royal Melbourne Hospital
Consultant Infectious Diseases Physician
Department of Infectious Diseases
Royal Melbourne Hospital and Alfred Hospital
Melbourne, Australia
Senior Scientific Director
Executive Vice President
Scientific Director
This program has been made available online.
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
Download free slides reviewing the latest updates on COVID-19 epidemiology and emerging data on diagnosis, symptoms, management, and treatment
Dr. Roger Paredes reviews safety and efficacy data on COVID-19 vaccines and considerations for vaccine rollout from Clinical Care Options (CCO)
Vikramjit Mukherjee, MD, provides a brief update on COVID-19 and answers clinician questions in the CCO Infectious Disease podcast
Review frequently asked questions and answers from expert CCO faculty on rapidly evolving data on COVID-19 vaccines and immunity
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.